AU770307B2 - PGE synthase and methods and means for modulating its activity - Google Patents
PGE synthase and methods and means for modulating its activity Download PDFInfo
- Publication number
- AU770307B2 AU770307B2 AU15041/00A AU1504100A AU770307B2 AU 770307 B2 AU770307 B2 AU 770307B2 AU 15041/00 A AU15041/00 A AU 15041/00A AU 1504100 A AU1504100 A AU 1504100A AU 770307 B2 AU770307 B2 AU 770307B2
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- pge
- pge synthase
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
- G01N33/553—Metal or metal coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003271297A AU2003271297B2 (en) | 1998-11-09 | 2003-12-19 | PGE synthase and methods and means for modulating its activity |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10768798P | 1998-11-09 | 1998-11-09 | |
| US60/107687 | 1998-11-09 | ||
| PCT/EP1999/008363 WO2000028022A1 (en) | 1998-11-09 | 1999-11-02 | Pge synthase and methods and means for modulating its activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003271297A Division AU2003271297B2 (en) | 1998-11-09 | 2003-12-19 | PGE synthase and methods and means for modulating its activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU1504100A AU1504100A (en) | 2000-05-29 |
| AU770307B2 true AU770307B2 (en) | 2004-02-19 |
Family
ID=22317930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU15041/00A Expired AU770307B2 (en) | 1998-11-09 | 1999-11-02 | PGE synthase and methods and means for modulating its activity |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US6395502B1 (https=) |
| EP (1) | EP1129188B1 (https=) |
| JP (2) | JP4503849B2 (https=) |
| AT (1) | ATE305040T1 (https=) |
| AU (1) | AU770307B2 (https=) |
| CA (1) | CA2349529C (https=) |
| DE (1) | DE69927400T2 (https=) |
| ES (1) | ES2249042T3 (https=) |
| WO (1) | WO2000028022A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000028022A1 (en) * | 1998-11-09 | 2000-05-18 | Karolinska Innovations Ab | Pge synthase and methods and means for modulating its activity |
| US7169580B1 (en) | 2000-02-03 | 2007-01-30 | Chugai Seiyaku Kabushiki Kaisha | Protein having PGE2 synthase activity and use thereof |
| AU2002323358A1 (en) * | 2001-08-24 | 2003-03-10 | Karoliska Innovations Ab | Methods for preparing purified prostaglandin e synthase |
| JP2005510220A (ja) * | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | プロスタグランジンe合成酵素2遺伝子の破壊 |
| JP2006500066A (ja) * | 2002-09-25 | 2006-01-05 | ファルマシア・コーポレーション | ミクロソームのプロスタグランジンe2シンターゼ発現のアンチセンス調節 |
| WO2004067766A1 (en) * | 2003-01-27 | 2004-08-12 | Pfizer Products Inc. | Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2 |
| WO2005024059A2 (en) * | 2003-09-09 | 2005-03-17 | Karolinska Innovations Ab | Methods for identifying compounds for inhibiting fever |
| US7638331B2 (en) | 2004-01-02 | 2009-12-29 | The Administration of the Tulane Rducation Fund | Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery |
| US20090088400A1 (en) * | 2007-09-11 | 2009-04-02 | Puymirat Jack | Prostaglandin e2 modulation and uses thereof |
| CN117323320B (zh) * | 2023-11-20 | 2025-10-31 | 复旦大学附属中山医院 | 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US914356A (en) * | 1901-11-30 | 1909-03-02 | Harry Ward Leonard | Electric-circuit controller. |
| AU750187B2 (en) * | 1997-09-17 | 2002-07-11 | Johns Hopkins University, The | P53-induced apoptosis |
| WO2000028022A1 (en) * | 1998-11-09 | 2000-05-18 | Karolinska Innovations Ab | Pge synthase and methods and means for modulating its activity |
-
1999
- 1999-11-02 WO PCT/EP1999/008363 patent/WO2000028022A1/en not_active Ceased
- 1999-11-02 CA CA002349529A patent/CA2349529C/en not_active Expired - Lifetime
- 1999-11-02 AT AT99957275T patent/ATE305040T1/de not_active IP Right Cessation
- 1999-11-02 ES ES99957275T patent/ES2249042T3/es not_active Expired - Lifetime
- 1999-11-02 EP EP99957275A patent/EP1129188B1/en not_active Expired - Lifetime
- 1999-11-02 AU AU15041/00A patent/AU770307B2/en not_active Expired
- 1999-11-02 JP JP2000581189A patent/JP4503849B2/ja not_active Expired - Lifetime
- 1999-11-02 DE DE69927400T patent/DE69927400T2/de not_active Expired - Lifetime
- 1999-11-04 US US09/433,466 patent/US6395502B1/en not_active Expired - Lifetime
-
2002
- 2002-03-28 US US10/109,438 patent/US7067296B2/en not_active Expired - Lifetime
-
2004
- 2004-10-07 US US10/962,155 patent/US7192733B2/en not_active Expired - Lifetime
-
2007
- 2007-02-27 US US11/679,585 patent/US7645601B2/en not_active Expired - Lifetime
-
2010
- 2010-01-21 JP JP2010011053A patent/JP2010115205A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| EMBL AU NO. AF 027740 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050118696A1 (en) | 2005-06-02 |
| US20080153107A1 (en) | 2008-06-26 |
| JP2002539762A (ja) | 2002-11-26 |
| EP1129188A1 (en) | 2001-09-05 |
| CA2349529C (en) | 2009-10-27 |
| US20030064493A1 (en) | 2003-04-03 |
| US6395502B1 (en) | 2002-05-28 |
| EP1129188B1 (en) | 2005-09-21 |
| ATE305040T1 (de) | 2005-10-15 |
| JP2010115205A (ja) | 2010-05-27 |
| CA2349529A1 (en) | 2000-05-18 |
| WO2000028022A1 (en) | 2000-05-18 |
| US7645601B2 (en) | 2010-01-12 |
| DE69927400D1 (de) | 2006-02-02 |
| JP4503849B2 (ja) | 2010-07-14 |
| ES2249042T3 (es) | 2006-03-16 |
| US7192733B2 (en) | 2007-03-20 |
| US7067296B2 (en) | 2006-06-27 |
| DE69927400T2 (de) | 2006-06-29 |
| AU1504100A (en) | 2000-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7645601B2 (en) | Methods and means for modulating PGE synthase activity | |
| Dingus et al. | G Protein βγ dimer formation: Gβ and Gγ differentially determine efficiency of in vitro dimer formation | |
| Soupene et al. | Activity of the acyl-CoA synthetase ACSL6 isoforms: role of the fatty acid Gate-domains | |
| Ruan et al. | Amino-terminal topology of thromboxane synthase in the endoplasmic reticulum. | |
| JP2005534279A (ja) | 新規なシクロオキシゲナーゼ変異体とその使用方法 | |
| AU2003271297B2 (en) | PGE synthase and methods and means for modulating its activity | |
| Bechor et al. | p67 phox binds to a newly identified site in Nox2 following the disengagement of an intramolecular bond—Canaan sighted? | |
| JP2013510574A (ja) | チャイニーズハムスターからのグリコシルトランスフェラーゼおよび関連方法 | |
| JP2003528638A (ja) | 単離ヒト薬剤代謝タンパク、ヒト薬剤代謝タンパクをコード化する核酸分子、及びその使用 | |
| WO2005019472A1 (ja) | シノビオリン活性調節作用の検出方法 | |
| JP2005526483A (ja) | 精製されたプロスタグランジンeシンターゼを調製するための方法 | |
| Pettersson et al. | Human microsomal prostaglandin E synthase 1: a member of the MAPEG protein superfamily | |
| Monfregola et al. | Functional analysis of TMLH variants and definition of domains required for catalytic activity and mitochondrial targeting | |
| Kojima et al. | SH1 (cysteine 717) of smooth muscle myosin: its role in motor function | |
| Svartz et al. | Leukotriene C4 synthase homo-oligomers detected in living cells by bioluminescence resonance energy transfer | |
| JP2007520208A (ja) | コア2β−1,6−N−アセチルグリコサミニルトランスフェラーゼの変異体 | |
| JPH10117788A (ja) | ヒト・myt−1キナーゼクローン | |
| US20090312245A1 (en) | SRA binding protein | |
| US6262234B1 (en) | Nuclear receptor polypeptide ZPPAR4 | |
| JP2002300880A (ja) | 新規ユビキチン特異プロテアーゼ | |
| JP2002519034A (ja) | ヒト酸化還元酵素タンパク質 | |
| WO2004058957A2 (en) | Canine cyp1a2 sequences | |
| JP2004065248A (ja) | 核内受容体リガンド検出剤、組換えタンパク質、発現用遺伝子、組換えベクター、形質転換体、核内受容体リガンド検出方法、及び、核内受容体リガンド検出キット | |
| WO2002079501A1 (en) | Methods and reagents for identifying weight loss promoters and therapeutic uses therefor | |
| JP2001302692A (ja) | IκBαのユビキチン化を阻害しうる試験化合物をスクリーニングする為の競合試験およびキット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |